December 9, 2019

France's Sanofi to buy immuno-oncology specialist Synthorx

Sanofi will pay $2.5 billion for the US company
Sanofi will pay $2.5 billion for the US company

French pharmaceutical giant Sanofi said on Monday it had agreed to buy US biotech firm Synthorx to boost its immuno-oncology portfolio.

Sanofi said it will pay $2.5 billion for the US company which specialises in treatments prolonging and improving the lives of cancer patients or those with auto-immune disorders.

Immuno-oncology therapies aim to mobilise the body's to fight .

California-based Synthorx has developed a way to expand the human genetic code by adding a new DNA base pair in what it says is a "first-of-its-kind" approach boosting the chances of cancer therapies to be effective.

The French company is paying $68 in cash for Synthorx, valuing the target company's stock at 172 percent above its closing price on Friday.

The acquisition is "aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations," Sanofi CEO Paul Hudson said in a statement.

Sanofi is present in 100 countries and employs more than 100,000 people.

© 2019 AFP

Citation: France's Sanofi to buy immuno-oncology specialist Synthorx (2019, December 9) retrieved 24 April 2024 from https://medicalxpress.com/news/2019-12-france-sanofi-immuno-oncology-specialist-synthorx.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Sanofi buys US haemophilia treatment firm for $11.6 bn (Update)
3 shares

Feedback to editors
Alteration of brain network condition could predict painful vaso-occlusive crisis in patients with sickle cell disease

1 hour ago
Trials reveal that internet-based conversations help sustain brain function in older adults

1 hour ago
Study finds that a dash of exercise can help students focus and enjoy university lectures

1 hour ago
New device improves stem cell generation and chance for accessible Alzheimer's cell therapy

1 hour ago
COVID-19 pandemic alters view that doctors are obligated to provide care: Study

1 hour ago
Genetics predict type 2 diabetes risk and disparities in childhood cancer survivors

1 hour ago
New algorithm could provide early warning for asthma attacks

1 hour ago
Circadian rhythms can influence drugs' effectiveness

2 hours ago
Artificial sweetener has potential to damage gut, finds study

2 hours ago
Researchers identify novel gene networks associated with aggressive type of breast cancer

2 hours ago
Load comments (0)